https://doi.org/10.55788/161e85e9
Androgenetic alopecia is the most common form of alopecia, which affects primarily men but also 20‒50% of patients are women, particularly after menopause. First-line treatments are topical minoxidil and oral finasteride for men, but many patients do not respond sufficiently, and it often takes very long to show effective results. Dr Michela Starace (University of Bologna, Italy) and her team realised the need for adjuvants and newer modalities of treatment to give faster and better outcomes [1]. Therefore, they explored whether non-pharmacological products could increase the effectiveness of treatment for androgenetic alopecia and telogen effluvium.
They formulated a topical treatment including oligopeptides with growth-factor mimicking activity, caffeine, taurine, and a lactoferrin-based iron-chelating complex (GFM-DA gel) and assessed its effectiveness when combined with topical minoxidil and oral finasteride. The gel was administered as add-on treatment once weekly. The 2 combination study arms were compared with 2 control groups that were treated with topical minoxidil or oral finasteride only. All study participants had androgenetic alopecia exceeding grade III, including grades IV and V on the Norwood-Hamilton scale. The primary endpoint was the change in the 7-point Global Photographic Assessment score (GPAS) from baseline to week 12 and 24.
At 12 weeks, the GPAS scores were 1.6 in the minoxidil and 1.1 in the finasteride monotherapy group compared with 1.6 in the group that applied the gel together with minoxidil and 1.8 in the gel-finasteride combination group. Treatment efficacy increased up to week 24: At this time, GPAS scores were 2.2 in the minoxidil only group, 2.4 in the minoxidil plus gel group, 1.9 in the finasteride group, and 2.7 in the group that was treated with both oral finasteride and the gel. The gel was generally well-tolerated.
Dr Starace concluded that adding a once-weekly topical gel containing caffein, growth-factor mimicking agents, taurine, and an iron-chelating complex to androgenetic alopecia drugs produced clinically better results, especially when used together with oral finasteride.
- Starace M, et al. Efficacy and tolerability of a gel formulation based on mimicking growth factors oligopeptides, taurine and caffeine in adrogenic alopecia subjects treated with topical minoxidil or oral finasteride: A prospective, assessor-blinded, parallel groups study. FC04.09, EADV Congress 2022, Milan, Italy, 7‒10 September.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Deuruxolitinib achieves hair regrowth, even in patients with severe alopecia areata Next Article
Long-term improvement in alopecia areata with ritlecitinib therapy »
« Deuruxolitinib achieves hair regrowth, even in patients with severe alopecia areata Next Article
Long-term improvement in alopecia areata with ritlecitinib therapy »
Table of Contents: EADV 2022
Featured articles
Letter from the Editor
Psoriasis and Psoriatic Arthritis: What You Need to Know
Novel oral psoriasis drug maintains efficacy over 2 years
A3 adenosine receptor agonist showed modest efficacy but excellent tolerability
Selective IL-23 inhibitor achieves long-term disease control in many patients with active PsA
AI machine learning algorithm useful in early detection of PsA
Novel Developments in Sun Protection
Myths regarding “health benefit” of suntan prevail in majority of population
Fern extract reverses severe actinic keratosis lesions
Vitiligo in 2022
Enhancing re-pigmentation rates with topical ruxolitinib in all body areas
Markedly lower skin cancer risk in vitiligo patients
Pruritus Treatment: Novel Agents Entering the Arena
Dupilumab leads to clinically relevant improvements in signs and symptoms of prurigo nodularis
Nalbuphine: aspiring to become another treatment for prurigo nodularis?
Notalgia paresthetica: may κ-opioid receptor agonists be a long-awaited effective therapy?
Pharmacotherapy in Hidradenitis Suppurativa: New Opportunities
High potential for secukinumab as next biologic treatment for HS
Hidradenitis suppurativa: TYK2/JAK1 inhibitor shows promise
Best of the Posters
High rate of non- or partial responders jeopardises therapeutic success in HS
Genital psoriasis: high prevalence, often underdiagnosed
Decreased overall survival in melanoma patients with low vitamin D
News in Atopic and Seborrheic Dermatitis
Baricitinib possible therapeutic option for children with AD
Amlitelimab therapy leads to sustained decrease of IL-22 in AD patients
IL-13 inhibition with lebrikizumab shows high maintenance rates in AD
Does 8 weeks of emollients use prevent AD in high-risk infants?
Roflumilast foam led to high response rates in seborrheic dermatitis
What Is Hot in Hair Disorders?
Long-term improvement in alopecia areata with ritlecitinib therapy
Topical gel plus finasteride beneficial for patients with androgenetic alopecia
Deuruxolitinib achieves hair regrowth, even in patients with severe alopecia areata
Related Articles
November 5, 2022
Letter from the Editor
November 5, 2022
Genital psoriasis: high prevalence, often underdiagnosed
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com